摘要
婴儿血管瘤是常见的婴幼儿良性肿瘤，对于增生期的血管瘤应早期治疗，防止严重并发症的发生。普萘洛尔是临床常用的非选择性β肾上腺素受体阻滞剂。近年来，越来越多的研究报道普萘洛尔治疗婴儿血管瘤取得较好的疗效，其可能机制包括抑制血管内皮生长因子的生成、抑制低氧诱导性因子-1α-血管内皮生长因子-A血管发生轴、促使基质金属蛋白酶的下调、以及降低血管瘤的内皮一氧化氮合酶等。
Infancy hemangiomas （IHs） are the most common benign tumor of infancy. Early therapy has been recommended for proliferating IHs to prevent serious complications. As a non selective beta-adrenergic receptor antagonist, propranolol is commonly used in clinical practice. Recently, more and more studies have reported that pmpranolol has a good efficacy in the treatment of IHs. The possible therapeutic mechanisms of propranolol in IH include suppression of vascular endothelial growth factor （VEGF） production, inhibition of the hypoxia-inducible factor 1 （HIF-1） α-VEGF-A axis, downregulation of matrix metalloproteinases （MMPs） and endothelial nitric oxide synthase, and so on.
出处
《国际皮肤性病学杂志》
2013年第3期156-160,共5页
International Journal of Dermatology and Venereology
关键词
血管瘤
婴儿
普萘洛尔
Hemangiomas
Infancy
Propranolol
